Search Results - "Moors, Ellen H. M"

A standardised framework to identify optimal animal models for efficacy assessment in drug development by Ferreira, Guilherme S, Veening-Griffioen, Désirée H, Boon, Wouter P C, Moors, Ellen H M, Gispen-de Wied, Christine C, Schellekens, Huub, van Meer, Peter J K

“…Poor translation of efficacy data derived from animal models can lead to clinical trials unlikely to benefit patients-or even put them at risk-and is a…”
Get full text

To what extent are the antimalarial markets in African countries ready for a transition to triple artemisinin-based combination therapies? by de Haan, Freek, Bolarinwa, Oladimeji Akeem, Guissou, Rosemonde, Tou, Fatoumata, Tindana, Paulina, Boon, Wouter P C, Moors, Ellen H M, Cheah, Phaik Yeong, Dhorda, Mehul, Dondorp, Arjen M, Ouedraogo, Jean Bosco, Mokuolu, Olugbenga A, Amaratunga, Chanaki

“…Triple artemisinin-based combination therapies (TACTs) are being developed as a response to artemisinin and partner drug resistance in the treatment of…”
Get full text

Exploring the feasibility of introducing triple artemisinin-based combination therapy in the malaria treatment policy in Vietnam by Cao, Van Anh Thi, Nguyen, Thieu Quang, Le Quyen, Duong, Boon, Wouter P. C, Moors, Ellen H. M, Dondorp, Arjen M, de Haan, Freek, Amaratunga, Chanaki

“…Abstract Background This study investigates the processes regarding changing malaria treatment policies in Vietnam. Moreover, it explores the feasibility of…”
Get full text

The impact of anti-malarial markets on artemisinin resistance: perspectives from Burkina Faso by Guissou, Rosemonde M, Amaratunga, Chanaki, de Haan, Freek, Tou, Fatoumata, Cheah, Phaik Yeong, Yerbanga, R Serge, Moors, Ellen H M, Dhorda, Mehul, Tindana, Paulina, Boon, Wouter P C, Dondorp, Arjen M, Ouédraogo, Jean Bosco

“…Widespread artemisinin resistance in Africa could be catastrophic when drawing parallels with the failure of chloroquine in the 1970s and 1980s. This article…”
Get full text

Strategies for deploying triple artemisinin-based combination therapy in the Greater Mekong Subregion by de Haan, Freek, Amaratunga, Chanaki, Thi, Van Anh Cao, Orng, Long Heng, Vonglokham, Manithong, Quang, Thieu Nguyen, Lek, Dysoley, Boon, Wouter P. C, Dondorp, Arjen M, Moors, Ellen H. M

“…Abstract Background This is a qualitative study to identify implementation challenges for deploying triple artemisinin-based combination therapy (TACT) in the…”
Get full text

Valuing health technology – habilitating and prosthetic strategies in personal health systems by Peine, Alexander, Moors, Ellen H.M.

“…This paper explores the tensions in ICT-driven personal health systems innovation and the impact of these tensions on valuing health innovation for older…”
Get full text

Exploring dynamics and strategies of niche protection by Boon, Wouter P.C., Moors, Ellen H.M., Meijer, Albert J.

“…•We study dynamics of protection in different phases of niche development.•Niche protection is explored in HIV and pandemic influenza cases.•Interactions…”
Get full text

Correction: A standardised framework to identify optimal animal models for efficacy assessment in drug development by Ferreira, Guilherme S, Veening-Griffioen, Désirée H, Boon, Wouter P C, Moors, Ellen H M, Gispen-de Wied, Christine C, Schellekens, Huub, van Meer, Peter J K

“…[This corrects the article DOI: 10.1371/journal.pone.0218014.]…”
Get full text

Translatability of preclinical to early clinical tolerable and pharmacologically active dose ranges for central nervous system active drugs by Ferreira, Guilherme S., Dijkstra, Francis M., Veening-Griffioen, Désirée H., Boon, Wouter P. C., Schellekens, Huub, Moors, Ellen H. M., van Meer, Peter J. K., Stuurman, Frederik E., van Gerven, Joop M. A.

“…The primary purpose of this study was to assess the translatability of preclinical to early clinical tolerable and pharmacologically active dose ranges for…”
Get full text

Implementation of artificial intelligence (AI) applications in radiology: hindering and facilitating factors by Strohm, Lea, Hehakaya, Charisma, Ranschaert, Erik R., Boon, Wouter P. C., Moors, Ellen H. M.

“…Objective The objective was to identify barriers and facilitators to the implementation of artificial intelligence (AI) applications in clinical radiology in…”
Get full text

Institutional power play in innovation systems: The case of Herceptin by Kukk, Piret, Moors, Ellen H.M., Hekkert, Marko P.

“…•We combine TIS framework with insights from institutional change literature.•We show how institutional change depends on other system building activities.•We…”
Get full text

The role of Periodic Safety Update Reports in the safety management of biopharmaceuticals by Ebbers, Hans C., Mantel-Teeuwisse, Aukje K., Sayed-Tabatabaei, Fakhredin A., Moors, Ellen H. M., Schellekens, Huub, Leufkens, Hubert G. M.

“…Purpose To describe and assess the outcomes of Periodic Safety Update Report (PSUR) evaluations of biopharmaceuticals. Methods A cross-sectional analysis was…”
Get full text

Gimme shelter? Heterogeneous preferences for tangible and intangible resources when choosing an incubator by van Weele, Marijn A., van Rijnsoever, Frank J., Groen, Menno, Moors, Ellen H. M.

“…The rapidly growing and diversifying incubator population has led to increasing efforts to understand why entrepreneurs prefer one incubator over another…”
Get full text

Levelling the Translational Gap for Animal to Human Efficacy Data by Ferreira, Guilherme S, Veening-Griffioen, Désirée H, Boon, Wouter P C, Moors, Ellen H M, van Meer, Peter J K

“…Reports of a reproducibility crisis combined with a high attrition rate in the pharmaceutical industry have put animal research increasingly under scrutiny in…”
Get full text

177Lu-PSMA for advanced prostate cancer: are we ready to play big? by Hehakaya, Charisma, Moors, Ellen H. M., Verkooijen, Helena M., Grobbee, Diederick E., Verburg, Frederik A., Lam, Marnix G. E. H.

Get full text

Problems and Promises of Introducing the Magnetic Resonance Imaging Linear Accelerator Into Routine Care: The Case of Prostate Cancer by Hehakaya, Charisma, Van der Voort van Zyp, Jochem R, Lagendijk, Jan J W, Grobbee, Diederick E, Verkooijen, Helena M, Moors, Ellen H M

“…The new radiotherapy high field, 1.5 Tesla MRI-guided linear accelerator (MR-Linac) is being clinically introduced. Sensing and evaluating opportunities and…”
Get full text

A Research Pathway Model for evaluating the implementation of practice-based research: The case of self-management health innovations by van Beest, Wilke, Boon, Wouter P C, Andriessen, Daan, Pol, Harald, van der Veen, Gerrita, Moors, Ellen H M

“…Abstract This study explores the evaluation of research pathways of self-management health innovations from discovery to implementation in the context of…”
Get full text

Tradition, not science, is the basis of animal model selection in translational and applied research by Veening-Griffioen, Désirée H, Ferreira, Guilherme S, Boon, Wouter P C, Gispen-de Wied, Christine C, Schellekens, Huub, Moors, Ellen H M, Van Meer, Peter J K

“…National and international laws and regulations exist to protect animals used for scientific purposes in translational and applied research, which includes…”
Get full text

A Cohort Study Exploring Determinants of Safety-Related Regulatory Actions for Biopharmaceuticals by Ebbers, Hans C., Mantel-Teeuwisse, Aukje K., Moors, Ellen H. M., Tabatabaei, Fakhredin A. Sayed, Schellekens, Huub, Leufkens, Hubert G. M.

“…Background: The characteristics of biopharmaceuticals may require a tailored approach to their safety management. However, information on what tools and…”
Get full text

Caring for healthcare entrepreneurs — Towards successful entrepreneurial strategies for sustainable innovations in Dutch healthcare by Janssen, Maarten, Moors, Ellen H.M.

“…The sustainability of current healthcare systems is threatened by several societal developments, including an aging population, an increase of unmet medical…”
Get full text